Clinical TrialJun 9, 2026, 07:01 AM
Kymera Initiates Phase 1 KT-485 Trial; Triggers $20M Sanofi Payment
AI Summary
Kymera Therapeutics announced the dosing of the first participant in the first-in-human Phase 1 clinical trial for KT-485 (SAR447971), an oral IRAK4 degrader. This milestone triggered a $20 million payment from its partner Sanofi. The trial, conducted by Sanofi, will evaluate KT-485 in healthy volunteers and hidradenitis suppurativa patients. Kymera is eligible for up to $975 million in additional potential milestones and has an option for a 50/50 profit split in the US.
Key Highlights
- First participant dosed in Phase 1 clinical trial for KT-485 (SAR447971), an oral IRAK4 degrader.
- Trial evaluates KT-485 in adult healthy volunteers and hidradenitis suppurativa (HS) patients.
- Initiation of the Phase 1 trial triggered a $20 million milestone payment from Sanofi to Kymera.
- Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones.
- Sanofi is leading development, regulatory, and commercial efforts for the KT-485 program.
- Kymera has the option for a 50/50 profit split in the US and double-digit tiered royalties in ROW.
- The Phase 1 trial (NCT07629336) will evaluate safety, tolerability, and pharmacokinetics.
Price Impact
More from KYMR